Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...

Some of the common reasons why companies go through vertical FDI include lowering the cost of raw materials or taking advantage of cheaper labor. Foreign direct investment occurs when an entity ...

Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California 90095, United States ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertical Aerospace's VX4 prototype, which is currently under going piloted flight tests at its Flight Test Centre. (Photo: Business Wire) Mudrick Capital Management enters into investment ...

It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic. Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product ...

Learn more about the importance of sweat chloride (SwCl) in cystic fibrosis. Today Vertex CF medicines are treating over 68,000 people with CF across more than 60 countries on six continents. This ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...